Article

Systemic Sclerosis Causes Increased Disability Over Time

Disability worsens over time in patients with systemic sclerosis (SSc). Diffuse disease and severity of breathing problems are the strongest determinants of disability; others include joint pain and contractures, fatigue, and depression

Disability worsens over time in patients with systemic sclerosis (SSc). Diffuse disease and severity of breathing problems are the strongest determinants of disability; others include joint pain and contractures, fatigue, and depression.

Schnitzer and associates performed a multicenter, longitudinal study of 745 patients with SSc in the Canadian Scleroderma Research Group registry. The Health Assessment Questionnaire (HAQ) was used to assess disability. The baseline characteristics of interest were age, sex, disease duration, and disease subset. The time-dependent variables included study visit number and 5 disease-specific questions developed to be administered with the HAQ. Two types of models were used to determine the overall trend of the HAQ over time.

Disability in SSc worsened over time in all study models. The raw, or undifferentiated, change in HAQ score was 0.022 per year. After accounting for various levels of informative patient dropout, the increase in HAQ score ranged from 0.039 per year to 0.071 per year. Using the most conservative of these estimates, this was equivalent to an increase in the HAQ score of 0.12 over 3 years.

The authors noted that their data provide important prognostic information and have ramifications for future studies using the HAQ as the outcome measure.

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
© 2024 MJH Life Sciences

All rights reserved.